| P50 | author | Alessandra Casuccio | Q56615493 |
| | Claudio Adile | Q56937659 |
| | Renato Vellucci | Q57079467 |
| | Andrea Cortegiani | Q38545310 |
| P2093 | author name string | Arturo Cuomo | |
| | Patrizia Villari | |
| | Sebastiano Mercadante | |
| | Alessandro Valle | |
| P2860 | cites work | Inhaled methoxyflurane and intranasal fentanyl for prehospital management of visceral pain in an Australian ambulance service | Q28282414 |
| | Breakthrough pain: definition, prevalence and characteristics | Q33435886 |
| | The use of Instanyl® in the treatment of breakthrough pain in cancer patients: a 3-month observational, prospective, cohort study | Q33561309 |
| | Breakthrough pain in cancer patients: pathophysiology and treatment | Q33585770 |
| | Safety of intranasal fentanyl in the out-of-hospital setting: a prospective observational study | Q34387291 |
| | Intranasal fentanyl versus intravenous morphine in the emergency department treatment of severe painful sickle cell crises in children: study protocol for a randomised controlled trial. | Q36150411 |
| | Comparative review of the clinical use of intranasal fentanyl versus morphine in a paediatric emergency department | Q37363233 |
| | Pain management practices in paediatric emergency departments in Australia and New Zealand: a clinical and organizational audit by National Health and Medical Research Council's National Institute of Clinical Studies and Paediatric Research in Emerg | Q37519806 |
| | Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer | Q37701842 |
| | Intranasal fentanyl: from pharmacokinetics and bioavailability to current treatment applications | Q37774349 |
| | Intranasal fentanyl for pain control: current status with a focus on patient considerations | Q37875708 |
| | Fentanyl nasal spray for the treatment of cancer pain | Q37879143 |
| | Intranasal fentanyl for pain management in children: a systematic review of the literature | Q37922306 |
| | Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Bet 4: is intranasal fentanyl better than parenteral morphine for managing acute severe pain in children? | Q37958677 |
| | Pharmacotherapy for breakthrough cancer pain | Q37974707 |
| | Intranasal fentanyl in the treatment of acute pain--a systematic review | Q37977122 |
| | Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids. | Q37998744 |
| | Intranasal fentanyl spray: a novel dosage form for the treatment of breakthrough cancer pain | Q38046590 |
| | Intranasal fentanyl in the palliative care of newborns and infants | Q38047121 |
| | Pharmacokinetics of non-intravenous formulations of fentanyl | Q38055713 |
| | Considerations in selecting rapid-onset opioids for the management of breakthrough pain | Q38090468 |
| | A pilot study of nasal fentanyl for patient controlled treatment of cancer pain | Q39210601 |
| | Intranasal fentanyl versus fentanyl pectin nasal spray for the management of breakthrough cancer pain in doses proportional to basal opioid regimen | Q39211378 |
| | Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label | Q39223824 |
| | Long-term tolerability, efficacy and acceptability of fentanyl pectin nasal spray for breakthrough cancer pain | Q39268873 |
| | Use of intranasal fentanyl for the relief of pediatric orthopedic trauma pain | Q39274745 |
| | Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain | Q39297474 |
| | A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial | Q39297854 |
| | Role of intranasal fentanyl in breakthrough pain management in cancer patients | Q39801041 |
| | Intranasal fentanyl versus placebo for pain in children during catheterization for voiding cystourethrography | Q39898093 |
| | Single-dose and multi-dose delivery systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate pharmacokinetic study | Q42665988 |
| | Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. BET 1: intranasal fentanyl or diamorphine versus intravenous morphine for analgesia in adults | Q42924700 |
| | Pharmacokinetics, analgesic effect, and tolerability of a single preprocedural dose of intranasal fentanyl in patients undergoing drain removal after breast reduction or augmentation surgery: A prospective, randomized, double-blind, placebo-controll | Q42949197 |
| | Intranasal fentanyl for analgesia in the paediatric emergency department | Q43102423 |
| | The implementation of intranasal fentanyl for children in a mixed adult and pediatric emergency department reduces time to analgesic administration | Q43195716 |
| | Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microg for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension tr | Q43288823 |
| | Intranasal fentanyl paediatric clinical practice guidelines | Q43291772 |
| | A report on the long-term use of fentanyl pectin nasal spray in patients with recurrent breakthrough pain | Q44272068 |
| | Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study | Q44342328 |
| | Faster absorption and higher systemic bioavailability of intranasal fentanyl spray compared to oral transmucosal fentanyl citrate in healthy subjects | Q45019837 |
| | Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. | Q45994501 |
| | An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects | Q46533634 |
| | Population pharmacokinetic meta-analysis of intranasal fentanyl spray as a means to enrich pharmacokinetic information for patients with cancer breakthrough pain | Q47396018 |
| | Patient satisfaction with intranasal fentanyl for breakthrough pain | Q48157735 |
| | Equivalency of two concentrations of fentanyl administered by the intranasal route for acute analgesia in children in a paediatric emergency department: a randomized controlled trial | Q48271409 |
| | An economic evaluation of short-acting opioids for treatment of breakthrough pain in patients with cancer | Q48279154 |
| | Breakthrough pain: characteristics and impact in patients with cancer pain. | Q51089873 |
| P433 | issue | 5 | |
| P921 | main subject | fentanyl | Q407541 |
| P304 | page(s) | 1349-1354 | |
| P577 | publication date | 2014-10-29 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain | |
| P478 | volume | 23 | |